PMCB on Nasdaq
PharmaCyte Biotech, Inc.
American biological products company based in Las Vegas, incorporated in Nevada. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
- TickerPMCB on Nasdaq1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersLas Vegas, Nevada1
- Incorporated inNV3
- Business address3960 Howard Hughes Parkway, Suite 500, Las Vegas, Nv 891693
- Filer categoryNon-accelerated filer, Smaller reporting company3
- Legal formCorporation
See how the biggest companies compare on our leaderboards
Conduct a stability study on our final formulated product candidate as well as the cells from our Master Cell Bank (“MCB”);4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
-58.3%Return on equity2
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-04-30 | 2025-04-30 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development costs | $391.3K | $438.4K |
| Intangible asset impairment | $1.5M | $0 |
| General and administrative | $4.9M | $3.9M |
| Total operating expenses | $6.9M | $4.4M |
| Loss from operations | -$6.9M | -$4.4M |
| Interest income | $733.4K | $1.4M |
| Dividend income | $380.7K | $0 |
| Change in fair value of warrant liability | -$4.7M | $10.4M |
| Change in fair value of derivative liability | $1.1M | $2.2M |
| Change in fair value of convertible note receivable Femasys | $1.3M | $941.0K |
| Change in fair value of warrant asset Femasys | -$2.6M | -$2.1M |
| Change in fair value of investment QCLS | -$7.7M | $5.1M |
| Change in fair value of warrant assets QCLS | -$1.4M | -$2.4M |
| Gain on related party investment QCLS | $2.1M | $21.4M |
| Gain on legal settlement re-fair value of warrants | $106.0K | $0 |
| Issuance costs Series C convertible preferred stock and warrants | -$1.2M | $0 |
| Unrealized gain (loss) on marketable securities | -$412.3K | $66.3K |
| Loss on legal settlement | $0 | -$2.0M |
| Loss on issuance of Series C preferred stock | -$215.0K | $0 |
| Other expense, net | -$980 | -$965 |
| Total other income (expense), net | -$12.6M | $35.0M |
| Income tax benefit (expense) | $0 | $0 |
| Net income (loss) | -$19.4M | $30.7M |
| Preferred stock dividends | -$278.5K | -$1.1M |
| Undistributed income to Series B convertible preferred stock | $0 | -$3.0M |
| Preferred stock accretion | -$3.5M | -$3.2M |
| Net income (loss) attributable to common stockholders | -$23.2M | $23.4M |
| Basic income (loss) per share attributable to common stockholders | -$2.77 | $3.19 |
| Diluted income (loss) per share attributable to common stockholders | -$2.77 | $3.19 |
| Weighted average shares outstanding basic | 8.4M shares | 7.3M shares |
| Weighted average shares outstanding diluted | 8.4M shares | 7.3M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.2
| Period ending | 2026-04-30 | 2025-04-30 | 2024-04-30 |
|---|---|---|---|
| Cash and cash equivalents | $18.6M | $15.2M | |
| Marketable equity securities | $254.0K | $366.3K | |
| Dividends receivable | $240.8K | $0 | |
| Investment in preferred stock QCLS - current | $18.2M | $0 | |
| Warrant asset QCLS - current | $0 | $2.9M | |
| Convertible Note receivable Femasys - current | $0 | $3.7M | |
| Prepaid expenses and other current assets | $96.9K | $223.8K | |
| Total current assets | $37.4M | $22.4M | |
| Intangible assets | $0 | $1.5M | |
| Investment in preferred stock QCLS | $0 | $22.5M | |
| Warrant assets QCLS - non current | $8.8M | $5.7M | |
| Warrant assets Femasys | $480.0K | $3.1M | |
| Other assets | $7.7K | $7.7K | |
| Total other assets | $9.3M | $32.8M | |
| Total Assets | $46.8M | $55.2M | |
| Accounts payable | $271.1K | $399.2K | |
| Accrued expenses | $522.8K | $2.5M | |
| Accrued Series C dividends | $32.5K | $0 | |
| Total current liabilities | $826.4K | $2.9M | |
| Long-term portion of accrued expenses | $0 | $25.0K | |
| Warrant liability | $10.1M | $338.0K | |
| Derivative liability | $878.0K | $0 | |
| Total other liabilities | $10.9M | $363.0K | |
| Total Liabilities | $11.8M | $3.3M | |
| Contingently redeemable warrants | $417.0K | $0 | |
| Total temporary equity | $1.7M | $0 | |
| Preferred stock value | $0 | $0 | |
| Common stock, authorized: 200,000,000 shares, $0.0001 par value; 26,005,715 and 21,672,095 shares issued and 10,735,649 and 6,795,779 shares outstanding as of April 30, 2026 and April 30, 2025, respectively. | $2.6K | $2.2K | |
| Additional paid-in capital | $182.7M | $181.5M | |
| Accumulated deficit | -$104.4M | -$85.0M | |
| Treasury stock, at cost, 15,270,066 and 14,876,316 shares as of April 30, 2026, and 2025, respectively | -$45.0M | -$44.6M | |
| Accumulated other comprehensive loss | -$20.8K | -$23.9K | |
| Total stockholders equity | $33.3M | $51.9M | $27.6M |
| Total Liabilities, Temporary Equity and Stockholders Equity | $46.8M | $55.2M | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares issued | 26.0M shares | 21.7M shares | |
| Common stock, shares outstanding | 10.7M shares | 6.8M shares | |
| Treasury stock, common shares | 15.3M shares | 14.9M shares |
| Period ending | 2026-04-30 | 2025-04-30 | 2024-04-30 |
|---|---|---|---|
| Cash and cash equivalents | $18.6M | $15.2M | |
| Marketable equity securities | $254.0K | $366.3K | |
| Dividends receivable | $240.8K | $0 | |
| Investment in preferred stock QCLS - current | $18.2M | $0 | |
| Warrant asset QCLS - current | $0 | $2.9M | |
| Convertible Note receivable Femasys - current | $0 | $3.7M | |
| Prepaid expenses and other current assets | $96.9K | $223.8K | |
| Total current assets | $37.4M | $22.4M | |
| Intangible assets | $0 | $1.5M | |
| Investment in preferred stock QCLS | $0 | $22.5M | |
| Warrant assets QCLS - non current | $8.8M | $5.7M | |
| Warrant assets Femasys | $480.0K | $3.1M | |
| Other assets | $7.7K | $7.7K | |
| Total other assets | $9.3M | $32.8M | |
| Total Assets | $46.8M | $55.2M | |
| Accounts payable | $271.1K | $399.2K | |
| Accrued expenses | $522.8K | $2.5M | |
| Accrued Series C dividends | $32.5K | $0 | |
| Total current liabilities | $826.4K | $2.9M | |
| Long-term portion of accrued expenses | $0 | $25.0K | |
| Warrant liability | $10.1M | $338.0K | |
| Derivative liability | $878.0K | $0 | |
| Total other liabilities | $10.9M | $363.0K | |
| Total Liabilities | $11.8M | $3.3M | |
| Contingently redeemable warrants | $417.0K | $0 | |
| Total temporary equity | $1.7M | $0 | |
| Preferred stock value | $0 | $0 | |
| Common stock, authorized: 200,000,000 shares, $0.0001 par value; 26,005,715 and 21,672,095 shares issued and 10,735,649 and 6,795,779 shares outstanding as of April 30, 2026 and April 30, 2025, respectively. | $2.6K | $2.2K | |
| Additional paid-in capital | $182.7M | $181.5M | |
| Accumulated deficit | -$104.4M | -$85.0M | |
| Treasury stock, at cost, 15,270,066 and 14,876,316 shares as of April 30, 2026, and 2025, respectively | -$45.0M | -$44.6M | |
| Accumulated other comprehensive loss | -$20.8K | -$23.9K | |
| Total stockholders equity | $33.3M | $51.9M | $27.6M |
| Total Liabilities, Temporary Equity and Stockholders Equity | $46.8M | $55.2M | |
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares issued | 26.0M shares | 21.7M shares | |
| Common stock, shares outstanding | 10.7M shares | 6.8M shares | |
| Treasury stock, common shares | 15.3M shares | 14.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-04-30 | 2025-04-30 |
|---|---|---|
| Net income (loss) | -$19.4M | $30.7M |
| Gain on related party investment - QCLS | -$2.1M | -$21.4M |
| Issuance costs Series C preferred stock and warrants | $1.2M | $0 |
| Loss on issuance of Series C preferred stock | $215.0K | $0 |
| Gain on re-fair value of warrants | -$106.0K | $0 |
| Non-cash interest income | -$162.5K | -$300.0K |
| Non-cash warrant liability | $0 | $469.0K |
| Intangible asset impairment | $1.5M | $0 |
| Stock issued for compensation - RSUs | $892.5K | $0 |
| Stock-based compensation - options | $236.1K | $478.6K |
| Unrealized (gain) loss on marketable equity securities | $412.3K | -$66.3K |
| Change in fair value of warrant liability | $4.7M | -$10.4M |
| Change in fair value of derivative liability | -$1.1M | -$2.2M |
| Change in fair value of convertible note receivable - Femasys | -$1.3M | -$941.0K |
| Change in fair value of warrant assets - Femasys | $2.6M | $2.1M |
| Change in fair value of investment - QCLS | $7.7M | -$5.1M |
| Change in fair value of warrants - QCLS | $1.4M | $2.4M |
| (Increase) decrease in prepaid expenses and other current assets | -$251.4K | $36.0K |
| Increase (decrease) in accounts payable | -$128.1K | $9.8K |
| Increase (decrease) in accrued expenses | -$1.5M | $1.3M |
| Net cash used in operating activities | -$5.2M | -$3.0M |
| Investment in preferred stock and warrants - QCLS | -$3.0M | -$7.0M |
| Proceeds from investment note receivable | $5.0M | $0 |
| Net cash provided by (used in) investing activities | $2.0M | -$7.0M |
| Repurchase of common stock, net | -$401.6K | -$2.5M |
| Net proceeds from issuance of Series C preferred stock | $6.2M | $0 |
| Redemption of preferred stock | $0 | -$22.5M |
| Payment of Series C convertible preferred stock dividends | -$246.0K | $0 |
| Net proceeds from warrant exercise | $1.0M | $0 |
| Net cash provided by (used in) financing activities | $6.6M | -$25.0M |
| Effect of currency rate exchange on cash and cash equivalents | $3.1K | -$358 |
| Net increase (decrease) in cash and cash equivalents | $3.4M | -$35.0M |
| Cash paid during the year for income taxes | $0 | $0 |
| Accrual of Series C Convertible Preferred Stock dividends | $278.5K | $0 |
| Accretion of discounts to redemption value of Series C Preferred Stock | $3.5M | $0 |
| Initial fair value of investment in QCLS Series H preferred shares | $3.5M | $0 |
| Initial fair value of investment in QCLS Series H warrants | $1.6M | $0 |
| Non-cash derivative liability at initial fair value | $2.0M | $0 |
| Non-cash warrant liability at initial fair value | $5.2M | $0 |
| Non-cash conversion of Series C convertible stock | $2.2M | $0 |
| Change in fair value associated warrant exercises | $599.1K | $0 |
| Fair value of contingently redeemable placement agent warrants | $417.0K | $0 |
| Series B Convertible Preferred Stock dividends | $0 | $1.1M |
| Accretion of discounts to redemption value of Series B Convertible Preferred Stock | $0 | $3.2M |
| Excise tax accrued on repurchase of common stock | $0 | $25.4K |
No quarter-by-quarter statement was filed.
Leadership
Who has led PharmaCyte Biotech, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chair
Chief financial officer
2010201520202025
- Chief executive officerKenneth Waggoner Aug 31, 2021 to Aug 31, 202114
- ChairKenneth Waggoner Aug 31, 2021 to Aug 31, 202114
- Chief financial officerCarlos Trujillo Sep 3, 2021 to Nov 22, 202315
- Chief financial officerMarylew Barnes Mar 30, 2009 to Mar 30, 200916
Board members and other officers (13)
- Chief Science OfficerGerald W. Crabtree Aug 31, 2021 to Aug 31, 202117
- Board memberMatthias Loehr Apr 11, 2022 to Apr 11, 202218
- Board memberDaniel Stuart Farb Aug 23, 2022 to Dec 30, 202219
- Board memberJack E. Stover Aug 23, 2022 to Aug 23, 202220
- Board memberJonathan Schechter Aug 23, 2022 to now21
- Board memberWayne Remell Walker Dec 30, 2022 to now22
- Board memberMichael M. Abecassis Aug 20, 2021 to now23
- Board memberRaymond Cf Tong Aug 20, 2021 to Aug 20, 202124
- Board memberThomas Liquard Aug 20, 2021 to Aug 20, 202125
- Board memberGerald W. Crabtree Aug 31, 2021 to Aug 31, 202117
- Board memberThomas C. K. Yuen Aug 31, 2021 to Aug 31, 202126
- Board memberCarlos Trujillo Sep 3, 2021 to Nov 22, 202315
- Board memberMarylew Barnes Mar 30, 2009 to Mar 30, 200916
Named in SEC Form D filings
People the company listed in its private-offering notices.
Former names
Timeline
- Aug 31, 2021New chief executive Kenneth Waggoner becomes CEO14
Filings
166 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 35 major events, 35 insider forms, 20 large holders, 1 private raises, 55 other. The latest 20:
- Sep 14, 202610-Q FORM 10-Q FOR JUL 2026 EDGAR
- Jul 29, 202610-K FORM 10-K FOR APRIL 2026 EDGAR
- Jul 17, 20264/A EDGAR
- Jul 17, 20264/A EDGAR
- Jul 17, 20264/A EDGAR
- Jul 17, 20264/A EDGAR
- Apr 2, 20264 EDGAR
- Apr 2, 20264 EDGAR
- Apr 2, 20264 EDGAR
- Apr 2, 20264 EDGAR
- Apr 2, 20268-K EDGAR
- Mar 17, 202610-Q FORM 10-Q FOR JAN 2026 EDGAR
- Mar 9, 2026ARS ANNUAL REPORT EDGAR
- Mar 9, 2026DEF 14A DEFINITIVE PROXY STATEMENT EDGAR
- Feb 27, 2026PRE 14A PRELIMINARY PROXY STATEMENT EDGAR
- Feb 13, 2026SCHEDULE 13G/A EDGAR
- Jan 7, 20264 EDGAR
- Jan 7, 20264 EDGAR
- Dec 18, 202510-Q FORM 10-Q FOR OCT 2025 EDGAR
- Dec 15, 2025NT 10-Q EXTENSION EDGAR
The 166 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
6 open-market trades by officers, directors and large owners since October 2021: 6 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jan 7, 2026 | Silverman JoshuaCEO and President | Buy | 40,000 | $0.83 | $33.2K | Form 4 |
| Jan 7, 2026 | SCHECHTER JONATHANDirector | Buy | 20,000 | $0.84 | $16.8K | Form 4 |
| Jan 6, 2026 | Silverman JoshuaCEO and President | Buy | 30,000 | $0.79 | $23.7K | Form 4 |
| Jan 6, 2026 | SCHECHTER JONATHANDirector | Buy | 20,000 | $0.79 | $15.8K | Form 4 |
| Jan 5, 2026 | Silverman JoshuaCEO and President | Buy | 30,000 | $0.78 | $23.4K | Form 4 |
| Jan 5, 2026 | SCHECHTER JONATHANDirector | Buy | 20,000 | $0.78 | $15.6K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- INTRACOASTAL CAPITAL, LLCSCHEDULE 13G/A, 7 filings Feb 11, 2022 to Feb 13, 202628
- Ayrton Capital LLCSCHEDULE 13G/A, 3 filings May 19, 2023 to Feb 13, 202529
- Iroquois Capital Management, LLCSC 13D/A, 6 filings Nov 4, 2021 to Jun 16, 202330
- Shay Capital LLCSC 13G/A, 2 filings Oct 20, 2022 to Feb 14, 202331
- SABBY MANAGEMENT, LLCSC 13G/A, 2 filings Jan 4, 2022 to Jan 10, 202332
Money raised
Private offerings the company reported to the SEC on Form D.
- Aug 17, 2025Raised $7 million in a private offering of equity Form D: 12 investors so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 27. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18SEC EDGARMatthias Loehr, Board member
- 19SEC EDGARDaniel Stuart Farb, Board member
- 20SEC EDGARJack E. Stover, Board member
- 21SEC EDGARJonathan Schechter, Board member
- 22SEC EDGARWayne Remell Walker, Board member
- 23SEC EDGARMichael M. Abecassis, Board member
- 24SEC EDGARRaymond Cf Tong, Board member
- 25SEC EDGARThomas Liquard, Board member
- 26SEC EDGARThomas C. K. Yuen, Board member
- 27
- 28
- 29
- 30
- 31
- 32